Press release
Osteoporosis Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential
Curious about the latest updates in the Osteoporosis Pipeline? Click here to explore the therapies and trials making headlines @ Osteoporosis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Osteoporosis Pipeline Report
* On 03 September 2025, Amgen conducted a study is to evaluate the efficacy of Prolia on lumbar spine BMD at 12 months.
* DelveInsight's Osteoporosis Pipeline report depicts a robust space with 30+ active players working to develop 35+ pipeline therapies for Osteoporosis treatment.
* The leading Osteoporosis Companies such as mAbxience, Alvotech, Transcenta Holding, Suzhou Suncadia Biopharmaceuticals, GlycoNex, Cellatoz Therapeutics, Enzo Biochem, Surrozen and others.
* Promising Osteoporosis Therapies such as Prolia, Romosozumab, Zoledronic Acid, Teriparatide, MK-5442, Alendronate Sodium, Teriparatide (PF708), AK156, AAE581, Bazedoxifene Acetate (TSE-424), and others.
Want to know which companies are leading innovation in Osteoporosis? Dive into the full pipeline insights @ Osteoporosis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Osteoporosis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Osteoporosis Pipeline Report also highlights the unmet needs with respect to Osteoporosis.
Osteoporosis Overview
Osteoporosis is a bone disease that develops when bone mineral density and bone mass decreases, or when the quality or structure of bone changes. This can lead to a decrease in bone strength that can increase the risk of fractures (broken bones). Osteoporosis is a "silent" disease because a person typically do not have symptoms, and may not even know that they have the disease until they break a bone.
Osteoporosis Emerging Drugs
* AVT03: Alvotech
AVT03 is a human monoclonal antibody and a biosimilar candidate to Prolia and Xgeva (denosumab). Denosumab targets and binds with high affinity and specificity to the RANK ligand membrane protein, preventing the RANK ligand/RANK interaction from occurring, resulting in reduced osteoclast numbers and function, thereby decreasing bone resorption and cancer-induced bone destruction. AVT03 is an investigational product and has not received regulatory approval in any country. Currently, the drug is in Phase III stage of its development for the treatment of osteoporosis.
* TST002: Transcenta Holding
TST002 (Blosozumab) is a humanized anti-sclerostin monoclonal antibody as a drug candidate for osteoporosis and other bone loss diseases. It has a dual effect possessing both anabolic and anti-resorptive effects, which stimulates bone formation and inhibits bone absorption, resulting in fast increase in bone mineral density and bone strength. Blocking sclerostin activity in human treated with anti-sclerostin antibody or with naturally occurring genetic deletion has been shown to be an effective approach in increasing bone mineral density (BMD) and reducing bone fracture. Currently, the drug is in Phase II stage of its clinical trial for the treatment of osteoporosis.
* Denosumab biosimilar: GlycoNex
GlycoNex, a Taiwanese biotech company, is developing a denosumab biosimilar called SPD8 for the treatment of osteoporosis. Denosumab is a fully human monoclonal antibody that inhibits receptor activator of nuclear factor kappa-B ligand (RANKL), a key regulator of osteoclast formation, function and survival. By blocking RANKL, denosumab reduces bone resorption and increases bone mineral density. GlycoNex recently reported positive results from a Phase I clinical trial of SPD8, which met its primary endpoint of pharmacokinetic equivalence to the reference product. Currently, the drug is in Phase II stage of its clinical trial for the treatment of osteoporosis.
If you're tracking ongoing Osteoporosis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Osteoporosis Treatment Drugs [https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Osteoporosis Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Osteoporosis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Osteoporosis Treatment.
* Osteoporosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Osteoporosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Osteoporosis market.
Osteoporosis Companies
mAbxience, Alvotech, Transcenta Holding, Suzhou Suncadia Biopharmaceuticals, GlycoNex, Cellatoz Therapeutics, Enzo Biochem, Surrozen and others.
Osteoporosis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Osteoporosis Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Stay ahead in Musculoskeletal Research - discover what's next for the Osteoporosis Treatment landscape in this detailed analysis @ Osteoporosis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Osteoporosis Pipeline Report
* Coverage- Global
* Osteoporosis Companies- mAbxience, Alvotech, Transcenta Holding, Suzhou Suncadia Biopharmaceuticals, GlycoNex, Cellatoz Therapeutics, Enzo Biochem, Surrozen and others.
* Osteoporosis Therapies- Prolia, Romosozumab, Zoledronic Acid, Teriparatide, MK-5442, Alendronate Sodium, Teriparatide (PF708), AK156, AAE581, Bazedoxifene Acetate (TSE-424), and others.
* Osteoporosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Osteoporosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Musculoskeletal Research - discover what's next for the Osteoporosis Treatment landscape in this detailed analysis @ Osteoporosis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Osteoporosis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Osteoporosis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* AVT03: Alvotech
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* TST002: Transcenta Holding
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Denosumab biosimilar: GlycoNex
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Osteoporosis Key Companies
* Osteoporosis Key Products
* Osteoporosis- Unmet Needs
* Osteoporosis- Market Drivers and Barriers
* Osteoporosis- Future Perspectives and Conclusion
* Osteoporosis Analyst Views
* Osteoporosis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=osteoporosis-pipeline-outlook-2025-insights-into-therapies-research-and-market-potential]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/osteoporosis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Osteoporosis Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential here
News-ID: 4174548 • Views: …
More Releases from ABNewswire
The Great Unroboting: AI-Text-Humanizer.com Improves the Human-AI Collaboration …
MUNICH, GERMANY - September 30, 2025 - As companies hurry to integrate Artificial Intelligence into their workflows, a critical challenge emerged: The loss of the human touch. From sales emails to internal memos - AI-generated communication is often generic, impersonal but also ineffective. AI-Text-Humanizer.com started its enterprise platform to solve this problem - to improve human-AI collaboration.
The drive for AI-powered efficiency has created a corporate communications crisis. Sales outreach emails…
Phenix City Medical Practice Announces Expanded Healthcare Services, Addressing …
Preferred Medical Group, Phenix City, announces the expansion of its healthcare services and improved patient access, addressing community demand for comprehensive medical care with integrated pediatric, adult, and therapeutic services under one roof.
Preferred Medical Group, Phenix City [https://preferredmedgroup.com/], has announced significant enhancements to its healthcare services, responding to increased community demand for accessible and comprehensive medical care. The medical practice, located at 3700 South Railroad Street, has introduced streamlined patient…
Auburn Medical Practice Expands Integrated Care Model as Primary Care Doctor Add …
Preferred Medical Group - Auburn expands ADHD services and integrated care model, offering comprehensive family medicine, behavioral health, and specialized attention disorder treatment in one convenient East Alabama location.
Preferred Medical Group - Auburn [https://preferredmedgroup.com/] has announced significant enhancements to its integrated healthcare services, responding to increased demand for ADHD treatment and comprehensive family medical care in East Alabama. The Auburn location, situated at 318 Samford Village Court, Suite 100, now…
Local ADHD Doctor Program Launches at Preferred Medical Group - Opelika for East …
Preferred Medical Group - Opelika launches an integrated ADHD treatment program that combines pediatric care, psychiatry, and therapy services to address regional healthcare needs for East Alabama families.
Opelika healthcare providers have taken a significant step toward addressing the growing need for specialized attention deficit hyperactivity disorder services in East Alabama. Preferred Medical Group - Opelika [https://preferredmedgroup.com/] has announced the expansion of comprehensive ADHD treatment programs, integrating pediatric care with behavioral…
More Releases for Osteoporosis
Rising Prevalence Of Osteoporosis Fuels Growth In The Osteoporosis Drug Market: …
The Osteoporosis Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Osteoporosis Drugs Market Size During the Forecast Period?
The market for medications for osteoporosis has seen a consistent rise in recent years. The current market value of $12.33 billion in 2024…
Rising Prevalence Of Osteoporosis Spurs Momentum In Postmenopausal Osteoporosis …
The Postmenopausal Osteoporosis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Postmenopausal Osteoporosis Treatment Market Size and Its Estimated Growth Rate?
The market for treatment of postmenopausal osteoporosis has seen a steady increase in size over the recent years. It's projected…
Osteoporosis Drug Market, By Type (Primary Osteoporosis and Secondary Osteoporos …
Osteoporosis is a condition of bone weakening or bones becomes fragile and likely to break. In other words, osteoporosis is a condition wherein the bone density decreases. This is specially witnessed in old age people. Osteoporosis brings along back pain, stooped posture, bone fracture and tooth loss.
View Detailed Report" https://www.databridgemarketresearch.com/reports/global-osteoporosis-drug-market
The global osteoporosis drug market is experiencing steady growth driven by factors such as the increasing aging population, rising prevalence of…
Osteoporosis Drugs: The Complete Review
Medication for osteoporosis increases bone mineral density and reduces fracture risk. Some osteoporosis medications promote bone growth while others reduce bone loss.
The bones may begin to deteriorate as age more quickly than the body can heal them. The doctor could determine that people have osteoporosis if they have significant bone density loss.
To receive free sample pages of this report@ https://www.psmarketresearch.com/market-analysis/osteoporosis-drugs-market/report-sample
Although osteoporosis cannot be treated, it can be slowed down or…
Osteoporosis Drugs Market: Demand for Osteoporosis Drugs High Among Geriatric Po …
The global osteoporosis drugs market is analyzed in a report by Transparency Market Research (TMR). The market is expected to grow due to the increasing geriatric population across the globe. The market for osteoporosis drugs is considered semi-consolidated as a handful of players hold a larger share in the market. As per the analysis, Novartis International AG, Eli Lilly and Company, Merck & Co. Inc., Pfizer Inc., and Amgen Inc.…
Global Postmenopausal Osteoporosis Therapeutics Market
The Postmenopausal Osteoporosis Therapeutics Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Osteoporosis is an orthopedic condition where the bone density and bone mass decreases and eventually increases the risk of bone fracture. Osteoporosis is one of the most common age related…
